BIO.News Newsletter

New polling data shows registered voters support Accelerated Approval—and hold policymakers responsible for ensuring access to new treatments. Plus: drug prices, food supply chains, and Glioblastoma (GBM) Awareness Day on a busy Friday. (702 words, 3 minutes, 30 seconds)P.S. It’s not too late to register for BIO Asia-Taiwan, happening July 27-31 both in Taipei and online—but hurry, because pre-registration closes on Wednesday, July 20! Get more details and register now.

The FDA has authorized the Novavax COVID-19 vaccine for emergency use, making it the fourth vaccine available in the U.S. We have the details, plus an exclusive interview with a Novavax executive. Plus, we take a look at how biotech is improving cosmetics and beauty products. (697 words, 3 minutes, 29 seconds)

The pandemic made antimicrobial resistance worse, says a new report released yesterday by the CDC. Meanwhile, with little progress reported from yesterday’s meeting between the U.S. and Mexican Presidents, it’s time we confirm the Chief Agricultural Negotiator at USTR, says BIO. (702 words, 3 minutes, 30 seconds)

We didn’t need a waiver of COVID vaccine intellectual property protections—we have vaccine oversupply. But we DO need a Chief Agricultural Negotiator at USTR, says BIO in a letter to Senate leadership ahead of Biden's meeting with Mexico's President today. We tell you why. (721 words, 3 minutes, 36 seconds)

Recess is over, and USDA is calling for increased investment in food and ag innovation by G20 members. Plus, a Bio.News exclusive opinion piece from BAKX Therapeutics’ CEO, who makes a case for “founder-centric biotech.” (701 words, 3 minutes, 30 seconds)

With health officials increasingly alarmed about the global spread of monkeypox, we have an exclusive interview on Bio.News with the CEO of SIGA Technologies, which manufactures an FDA-approved therapeutic being deployed against the virus. Plus, a new study shows consumers under 30 are more open to gene-edited foods, but consumer education remains essential. (710 words, 3 minutes, 33 seconds)

Senate Democrats released their latest plan for drug price controls yesterday—we have details and BIO’s take. Plus, Italy’s worst drought in 70 years is ravaging risotto rice—but biotech offers solutions for crops and climate change. (561 words, 2 minutes, 48 seconds)

A new study finds drug price controls would reduce cancer research funding by 31%. Meanwhile, BIO provides recommendations on how to improve regulatory frameworks at APHIS and advance plant and animal biotech solutions. (710 words, 3 minutes, 33 seconds)

We're back from the holiday weekend – and we're talking about drug price controls again. Here's what you need to know, plus new research that tells us how biotech can help stop mosquito-borne disease. (572 words, 2 minutes, 51 seconds)

Before the long weekend, we have a quick read about BIO members joining the White House’s Health Sector Climate Pledge and the FDA’s recommendation for fall booster shots. (434 words, 2 minutes, 10 seconds) We’ll be taking a quick break on Monday, July 4. We will resume publication on Tuesday, July 5. Enjoy the holiday weekend!